Published Date: 08 Mar 2023
The latest data on metformin in COVID show benefits in the disease.
Read Full Newsargenx's efgartigimod-alfa therapy was approved for seropositive generalized myasthenia gravis in 2021.
Early initiation of opicapone significantly reduces OFF time and enhances ON time in patients with recently diagnosed Parkinson's disease, improving overall treatment outcomes.
The FDA requested the full data from the phase 3 HOPE-3 study as part of its review of the biologics license application for deramiocel, which Capricor plans to submit in February 2026.
A five-year analysis from the National RLS Opioid Registry found that most patients with dopamine agonist augmented restless legs syndrome maintained stable, low-dose opioid therapy with sustained symptom control.
Personalized Care Improvements Identified for Older Patients with Skin Cancer
New Findings on Acne Incidence in Transgender Individuals, With Howa Yeung, MD, MSc
What to Expect at the 2026 Maui Derm Conference
1.
NEJM: Pirtobrutinib is effective in CLL patients who have received prior BTK inhibitor therapy.
2.
Study finds common genetic target may halt breast cancer cell growth
3.
A single-cell analysis reveals a distinctive immunosuppressive tumor microenvironment in kidney cancer brain metastases.
4.
automated, precise reporting for clonality testing using NGS.
5.
Kate Middleton Gives Cancer Update
1.
Bridging the Gap Between Cancer Treatment-Induced Cardiotoxicity and Regenerative Medicine
2.
Role of Type I Interferons and KDM1B in Driving Cancer Stemness and Therapeutic Evasion
3.
Discovering the Benefits of TNK: A Comprehensive Blog Article
4.
A Closer Look at Poorly Differentiated Carcinoma: Uncovering its Complexities
5.
Unlocking the Mystery of Elliptocytes: Exploring the Unusual Shape of Red Blood Cells
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
L858R Mutation- An Overview of Retrospective Cohort Study in Advanced NSCLC Patients
2.
Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL
3.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part II
4.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
5.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation